Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of JMT103 in Glucocorticoid Induced Osteoporosis
NCT05397938Phase 2Unknown
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of narlumosbart in glucocorticoid-induced osteoporosis (GIOP), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Status: unknown.
02
Drugs
narlumosbart
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on NCT05397938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05397938.